Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Genitourinary tumours, non-prostate

706MO - Association between human papillomavirus (HPV) infection and outcome of perioperative nodal radiotherapy for penile carcinoma


18 Sep 2020


Mini Oral - Genitourinary tumours, non-prostate


Tumour Site

Penile Cancer


Andrea Necchi


Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274


A. Necchi1, M. Bandini2, J.S. Ross3, Y. Zhu4, Y. Ding-Wei4, A. Ornellas5, N. Watkin6, B. Ayres6, O. Hakenberg7, A. Heidenreich8, D. Raggi1, P. Giannatempo9, L. Marandino10, J. Chipollini11, M. Azizi11, O. Brouwer12, D. Grass11, P. Johnstone11, M. Albersen13, P. Spiess11

Author affiliations

  • 1 Medical Oncology Dept., Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 2 Urology, San Raffaele Hospital, 20100 - Milan/IT
  • 3 Medical Director, Foundation Medicine, 12208 - Albany/US
  • 4 Urology, Fudan University, Shanghai/CN
  • 5 Urology, Hospital Mário Kröeff and Brazilian Cancer Institute,, Rio de Janeiro/BR
  • 6 Urology, St. George’s University Hospitals, NHS Foundation Trust, London/GB
  • 7 Urology, University Hospital Rostock, Rostock/DE
  • 8 Urology, Uniklinik Köln, 50937 - Cologne/DE
  • 9 Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 10 Medical Oncology Dept., Istituto Nazionale dei Tumori,, 20133 - Milano/IT
  • 11 Urology, Moffit Cancer Center, Tampa/US
  • 12 Urology, Netherlands Cancer Institute, Amsterdam/NL
  • 13 Urology, University Hospital Leuven, Leuven/BE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 706MO


Data related to the impact of human papillomavirus (HPV) infection status and the outcome of perioperative treatments in patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking. We aimed to analyze the benefit from perioperative radiotherapy (RT) according to HPV infection status.


Within an international, multicenter database of 1,254 patients (pts) with PSCC who received inguinal lymph node dissection (ILND) from Europe, United States, Brazil, United Kingdom and China, 507 had suitable clinical information. Kaplan-Meier and restricted mean survival time (RMST) examined the overall survival (OS) differences among HPV+ and HPV- patients according to the use of perioperative RT to involved regional lymph nodes. The analyses were also made after propensity score-matching (PSM; N=136). Multivariable Cox regression analyses for OS were also done. Finally, we looked at the genomic alterations landscape of PSCC from the Foundation Medicine database (N=199) to characterize HPV+ PSCC.


Pts with HPV+ PSCC exhibited a lower clinical N-stage (p<0.001) and ILNM density (p<0.001). HPV+ patients had similar median OS (p=0.1) but longer RMST than HPV- patients at different time-points. Nevertheless, HPV+ patients treated with perioperative RT exhibited longer median OS (p=0.015) and longer RMST compared to HPV- pts. These findings were not confirmed with perioperative chemotherapy (p=0.19). In the PSM cohorts, HPV+ status remained significantly associated with longer OS after RT. In multivariable Cox regression analyses, pts with HPV+ PSCC exhibited a significantly improved OS compared with those with HPV- PSCC (HR: 0.12, 95%CI: 0.03-0.48; p=0.003). Among the several different genomic alterations frequencies, the top-altered genes (>20%) in HPV+ cases were PI3KCA (38.7%) and KMT2D(25.8%), whereas in HPV- cases these were TP53 (75.2%), CDKN2A (65%) and TERT (promoter region, 60.2%).


Perioperative RT was more effective in the subgroup of HPV+ PSCC. Reasons for enhanced RTsensitivity may also be related to the different landscape of genomic alterations. These results should be considered as hypothesis-generating and may inspire future prospective trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.